Department of Pharmacy - Center for Drug Research
Office: B 4.002
Angiogenesis, the formation of new blood vessels is important for physiological (e.g. wound healing) and pathological (e.g. tumor growth) processes.
We are interested in inhibiting angiogenesis mainly in the tumor context as very promising therapeutic option. The molecular target structures we currently investigate are the kinase CDK5 and the cytoskeleton proteins tubulin and actin.
By using and characterizing novel inhibitors of natural origin (e.g. isolated from myxobacteria) we gain insight into basic cell biological questions, and try to establish innovative classes of potential therapeutics.
In a further approach, we try to understand basic concepts of angiogenesis by manipulating cellular behaviour via nanoagents. like, e.g. structured surfaces, hygrogels, nanoparticles or artificial membranes.
Dr. Christina Moser
Dr. Kerstin Kick
Dr. Simon Schuster
Dr. Julia Herzog
Dr. Magdalena Menhofer
Dr. Sebastian Rath
Dr. Sabine Weitensteiner
Dr. Johanna Liebl
Dr. Anja Koltermann
Dr. Andrea Rothmeier
DFG ZA 186/7-1: 'The role of CDK5 as target in hepatocellular carcinoma (HCC)'.
SFB 1032: 'Controlling cellular functions by structured surfaces. (Artificial angiogenesis)'.
Head of the Imaging Facility of the Department of Pharmacy
An up-to-date list of Prof. Dr. Zahler's publications can be found on PubMed.